NYXOAH S A Stock Price, News & Analysis

Nyxoah has announced the nomination of Raymond Cohen and Virginia Kirby for its Board of Directors, pending approval at the Annual Shareholders' Meeting on June 8, 2022. This follows the resignations of Don Deyo and Jan Janssen, maintaining eight board members. Cohen brings extensive experience from leading Axonics and Cardiac Science, while Kirby offers significant expertise in clinical and regulatory affairs within the medical device industry. Nyxoah specializes in solutions for Obstructive Sleep Apnea, with its Genio® system already CE marked and undergoing further FDA studies.

On June 8, 2022, NYXOAH SA (Euronext Brussels: NYXH) will hold its annual and extraordinary shareholders' meetings at 2:00 PM CET. Shareholders are encouraged to register from 1:30 PM CET, with measures in place due to COVID-19. Key agenda items include the approval of statutory annual accounts for 2021, remuneration reports, and changes to the remuneration policy to introduce share-based compensation for non-executive directors. Shareholders can participate remotely via video conference. Further details are available on the Company’s website.

Nyxoah has announced the release of its Q1 2022 financial results, scheduled for May 9, 2022, after market close. A conference call will follow on May 10, 2022, at 2:00 PM CET / 8:00 AM ET, enabling investors to discuss these results. The call can be accessed through various dialing options for attendees from the U.S., Belgium, and international locations. Nyxoah focuses on treating Obstructive Sleep Apnea with its lead solution, the Genio® system, which has received CE Mark approval and is currently under review for FDA clearance.

Nyxoah reported significant growth in its full-year 2021 results, generating revenue of €852,000 from the Genio® system commercialization, up from €69,000 in 2020, achieving a gross margin of 64.4%. The company made strides in Germany with a DRG code and secured reimbursement in Spain, while expanding its addressable market by 30% after receiving expanded CE mark approval. Despite a net loss of €27.6 million, up from €12.2 million in 2020, Nyxoah's cash position improved to €135.5 million after a successful IPO, positioning the company for continued operational momentum in 2022.

Nyxoah announced that its BETTER SLEEP clinical trial met its primary endpoint, demonstrating the effectiveness of hypoglossal nerve stimulation (HGNS) for treating patients with Complete Concentric Collapse (CCC) of the soft palate. The trial involved 42 moderate-to-severe obstructive sleep apnea patients, with a statistically significant reduction in apnea-hypopnea index (AHI4) of 11 points at six months. Over 60% responder rates were achieved across patient cohorts. The company aims for expanded therapeutic indications and ongoing collaboration with the FDA for clinical trials in the U.S.

Nyxoah SA announced its participation in the Oppenheimer 32nd Annual Healthcare Conference, scheduled for March 15-17, 2022. The company will present virtually with CEO Olivier Taelman providing a corporate update on March 16 at 10:40 am EST. Nyxoah specializes in innovative solutions for Obstructive Sleep Apnea (OSA) treatment, notably through its lead product, the Genio® system. This system received its CE Mark in 2019 and is currently being studied for FDA approval. Investors can access the live webcast and updated presentations via the company's investor relations page.

Nyxoah announced its participation at the World Sleep Congress 2022 in Rome, Italy, from March 11-16, 2022. The company will present data from its BETTER SLEEP clinical trial on March 14 and hold several physician events. The Genio® system, a breakthrough treatment for Obstructive Sleep Apnea (OSA), was highlighted. Nyxoah aims to improve therapies for patients with Complete Concentric Collapse (CCC) and is working towards securing FDA approval for clinical trials for CCC patients in the U.S.

Nyxoah SA will announce its 2021 financial results on March 24, 2022, after market close. A conference call for discussion is scheduled for March 25, 2022, at 2:00 PM CET / 8:00 AM ET. Investors can join by phone or via the company's investor relations website. Nyxoah specializes in treating Obstructive Sleep Apnea with its innovative Genio® system, which received CE Mark approval in 2019 and is currently under study for FDA approval.

Nyxoah SA has disclosed updated information on its voting rights and share capital as of February 11, 2022. The total share capital stands at EUR 4,431,664.69, with 25,797,359 ordinary shares now carrying voting rights. Furthermore, the company has several outstanding subscription rights, including 55 warrants from 2016 for 27,500 shares, 100 warrants from 2018 for 50,000 shares, 490,500 warrants from 2020 for 490,500 shares, and 1,400,000 warrants from 2021. This update complies with Article 15 of the Law of 2 May 2007 on large shareholdings.